Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.1.1.64: testosterone 17beta-dehydrogenase (NADP+)

This is an abbreviated version!
For detailed information about testosterone 17beta-dehydrogenase (NADP+), go to the full flat file.

Word Map on EC 1.1.1.64

Reaction

testosterone
+
NADP+
=
androstenedione
+
NADPH
+
H+

Synonyms

17-ketoreductase, 17beta-HSD, 17beta-HSD 3, 17beta-HSD type 3, 17beta-HSD type 5, 17beta-HSD-3, 17beta-HSD1, 17beta-HSD3, 17beta-HSD4, 17beta-HSD5, 17beta-hydroxysteroid dehydrogenase, 17beta-hydroxysteroid dehydrogenase 3, 17beta-hydroxysteroid dehydrogenase type 3, 17beta-hydroxysteroid dehydrogenase type 5, 17beta-hydroxysteroid dehydrogenases type 3, 17betaHSD3, 3beta-hydroxysteroid dehydrogenase type 3, AKR1C3, HSD17B3, More, NADP-dependent testosterone-17beta-oxidoreductase, type 3 17beta-HSD, type 3 17beta-hydroxysteroid dehydrogenase, type 5 17beta-hydroxysteroid dehydrogenase, type 5 beta-hydroxysteroid dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.64 testosterone 17beta-dehydrogenase (NADP+)

Expression

Expression on EC 1.1.1.64 - testosterone 17beta-dehydrogenase (NADP+)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
curcumin analog H10 inhibits the production of 17beta-HSD3 in vitro. It has no effect on the expression levels of 17beta-HSD3, 3betaHSD1, CYP17alpha1, CYP11alpha1, and STAR. H10 could serve as an effective inhibitor of 17beta-HSD3, which in turn would inhibit the biosynthesis of androgens and progression of prostate cancer
exposure of HCT-15 cells to cisplatin results in aquisition of cisplatin resistance and concomitant induction of isoform AKR1C3 and aldo-keto reductase AKR1C1 expression
in thrombocythemia, a rare myeloproliferative disorder, 17beta-HSD3 is down-regulated about 4.5fold
the enzyme (17beta-HSD3) is over-expressed in hormone-dependent prostate cancer. 17beta-HSD3 mRNA increases over 30fold in cancerous prostate biopsies and the enzyme is overexpressed 8fold in LuCaP-23 and LuCAP-35 cell lines, obtained from metastatic tissues of a patient resistant to castration therapy
the expression of isoform AKR1C3 is reduced in both hyperplastic and carcinomatous endometrial epithelium